Analysts Set Kalaris Therapeutics Inc. (NASDAQ:KLRS) Target Price at $14.00

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $14.00.

Several analysts recently commented on KLRS shares. Chardan Capital assumed coverage on Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Citizens Jmp assumed coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th.

Kalaris Therapeutics Trading Down 3.7%

NASDAQ:KLRS opened at $8.65 on Wednesday. The company has a market cap of $161.76 million, a PE ratio of -2.29 and a beta of -0.09. The company has a 50 day simple moving average of $9.02 and a two-hundred day simple moving average of $6.19. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KLRS. State Street Corp increased its position in Kalaris Therapeutics by 12.4% in the fourth quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after buying an additional 2,800 shares in the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kalaris Therapeutics during the 4th quarter valued at approximately $34,000. Johnson Financial Group Inc. purchased a new stake in Kalaris Therapeutics in the 3rd quarter worth approximately $58,000. Keel Point LLC bought a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $86,000. Finally, Walleye Capital LLC purchased a new position in Kalaris Therapeutics during the fourth quarter valued at approximately $95,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.